Form 8-K - Current report:
SEC Accession No. 0001213900-20-035296
Filing Date
2020-11-05
Accepted
2020-11-05 16:24:08
Documents
14
Period of Report
2020-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea129282-8k_nektartherap.htm   iXBRL 8-K 33355
2 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS THIRD QUARTER 2020 FINANCIAL R ea129282ex99-1_nektar.htm EX-99.1 103169
  Complete submission text file 0001213900-20-035296.txt   290401

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE nktr-20201105.xsd EX-101.SCH 3439
4 XBRL DEFINITION FILE nktr-20201105_def.xml EX-101.DEF 10725
5 XBRL LABEL FILE nktr-20201105_lab.xml EX-101.LAB 21618
6 XBRL PRESENTATION FILE nktr-20201105_pre.xml EX-101.PRE 11087
7 EXTRACTED XBRL INSTANCE DOCUMENT ea129282-8k_nektartherap_htm.xml XML 2473
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 201290834
SIC: 2834 Pharmaceutical Preparations